SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently under pressure following media reports that it may be exploring a significant equity raise to support its massive AI infrastructure and data center capital expenditure requirements. Investors are debating whether this potential dilution signifies a long-term strategic commitment to AI dominance or a sign of unsustainable spending, leaving the stock caught between concerns over shareholder impact and its core advertising business performance.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is experiencing extreme volatility and intense community speculation, driven by the massive concentration of high-bandwidth memory giants like Samsung and SK Hynix within its index. Traders are actively debating whether the current price action represents a sustainable super-cycle driven by AI chip demand or a dangerously overextended, leverage-fueled bubble prone to rapid sell-offs.

TON (The Open Network) is a general-purpose&nbsp;blockchain that allows developers to build decentralized apps and tokens.

Toncoin

Toncoin is attracting significant community attention as investors weigh the impact of its deep integration with the Telegram ecosystem against recent market volatility and technical resistance. While some traders are focused on the growth of Ton-based wallet activity and new institutional listings, others are debating the sustainability of current price levels amid ongoing concerns regarding token unlocks and structural market shifts.

Leidos Holdings, Inc. engages in providing services and solutions in the defense, intelligence, civil and health markets. It operates through the following three segments: Defense Solutions, Civil, and Health. The Defense Solutions segment provides services, solutions, and products focusing on digital modernization, mission systems and integration, command, control, computers, communications, intelligence, surveillance and reconnaissance technologies and services, maritime solutions, transformative software, analytics, intelligence analysis, mission support and logistics services, weapons systems and space systems and solutions. The Civil segment focuses on modernizing infrastructure, systems, and security. The Health segment offers solutions to federal and commercial customers that are responsible for the health and wellbeing of people worldwide including service members and veterans. The company was founded by John Robert Beyster on February 3, 1969 and is headquartered in Reston, VA.

Leidos Holdings Inc

Leidos Holdings is currently in the spotlight as investors track its strong performance across defense and digital modernization, underscored by a steady stream of high-value government contracts. The community is actively debating its valuation compared to peers and focusing on the company's expanding footprint in AI-driven security and defense infrastructure.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing extreme downward pressure, with community members expressing panic and frustration as the token hits multi-year lows. Many investors are debating whether these levels represent a rare buying opportunity or a signal of deeper structural failure, with sentiment largely split between those aggressively averaging down and those who believe the crypto sector is facing a terminal decline.

Ethereum Classic

Ethereum Classic is trending as frustrated investors debate its long-term viability against other major assets, with many expressing deep disappointment over stagnant price action. The community remains polarized, frequently comparing the token's current performance to its historical highs while split between those liquidating out of exhaustion and others doubling down in anticipation of a potential altcoin rally.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as investors monitor its strength relative to Bitcoin and anticipate its role in the AI agent economy, with community members actively discussing accumulation strategies and bullish long-term potential. Speculation regarding future enterprise adoption and the broader AI narrative continues to drive high engagement, despite ongoing debates about market volatility and supply dynamics.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is trending as investors digest the spin-off of its media assets into the newly independent Versant Media Group, with sentiment divided between those seeking bargain entry points at current valuations and skeptics concerned about structural headwinds in the cable sector. The community is actively debating the long-term viability of the legacy cable business versus potential growth from the remaining connectivity, theme parks, and streaming segments.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing intense investor interest as the April 30th PDUFA date for the Auvelity label expansion into Alzheimer's agitation approaches, with analysts increasingly confident in an approval. Community sentiment remains bullish, highlighting the drug's potential as a first-in-class treatment for an underserved market and viewing recent stock volatility as a buying opportunity ahead of anticipated regulatory success and upcoming earnings.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

The ProShares Bitcoin Strategy ETF is trending as investors grapple with its ongoing price volatility alongside broader market fluctuations in Bitcoin. Community discussion is heavily focused on the contrast between the ETF's consistent monthly dividend payouts and the NAV decay, with many debating whether to hold for income or shift into spot Bitcoin products.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 20.4% in April

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) was the target of a large drop in short interest in April. As of April 15th, there was short interest totaling 12,887 shares, a...

Molecular Partners (NASDAQ:MOLN) Given "Buy" Rating at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price target on shares of Molecular Partners in a report on Wednesday...

Molecular Partners (NASDAQ:MOLN) Stock Price Up 5%  - Still a Buy?

Molecular Partners (NASDAQ:MOLN) Trading Up 5% - Time to Buy...

Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Drops By 18.9%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 13th, there was short interest...

HC Wainwright Brokers Increase Earnings Estimates for MOLN

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Molecular Partners in a...

Molecular Partners' (MOLN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Molecular Partners in a research note on Monday...

Molecular Partners (NASDAQ:MOLN) Issues Quarterly Earnings Results

Molecular Partners (NASDAQ:MOLN - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus...

Will Petrobras Pull Off Q4 Earnings Beat on Strong Production?

PBR gears up for fourth-quarter results as pre-salt output hits 3,109 MBOE/d, but refining outages and weaker fuel production may weigh on margins.

Molecular Partners (MOLN) to Release Quarterly Earnings on Thursday

Molecular Partners (NASDAQ:MOLN) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...

Molecular Partners (NASDAQ:MOLN) Stock Price Down 1.5% - Should You Sell?

Molecular Partners (NASDAQ:MOLN) Trading Down 1.5% - Here's What Happened...

Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

MOLNMolecular Partners AG

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MOLN News